Intra-Cellular Therapies ... (ITCI)
NASDAQ: ITCI
· Real-Time Price · USD
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
Intra-Cellular Therapies Revenue Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant Revenue | 112K | 216K | 112K | 23K | 593K | 363K | 664K | 94.73M | 87.43M | 71.87M | 55.07M | 34.76M | 25.52M | 21.61M | 19.01M | 15.58M | 50.52K | n/a | 30.75K | 200.96K |
| Grant Revenue Growth | -48.15% | +92.86% | +386.96% | -96.12% | +63.36% | -45.33% | -99.30% | +8.35% | +21.65% | +30.50% | +58.46% | +36.21% | +18.10% | +13.68% | +22.00% | +30739.55% | n/a | -100.00% | -84.70% | n/a |
| Product Revenue | 360.5M | 175.16M | 161.28M | 144.84M | 131.51M | 125.81M | 110.13M | 575K | 436K | n/a | 505K | 241K | 154.9K | 601.04K | 1.04M | 299.42K | 12.4M | 7.37M | 1.88M | 882.52K |
| Product Revenue Growth | +105.81% | +8.61% | +11.35% | +10.14% | +4.53% | +14.24% | +19052.70% | +31.88% | n/a | -100.00% | +109.54% | +55.58% | -74.23% | -42.20% | +247.26% | -97.59% | +68.33% | +292.81% | +112.56% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 137.73M | 132.1M | 121.57M | 113.08M | 104.72M | 105.21M | 101.01M | 98.92M | 94.63M | 88.38M | 100.32M | 75.46M | 79.68M | 70.5M | 69.85M | 52.58M | 58.35M | 52.47M | 41.45M | 34.1M | 22.76M | 15.04M | 15.44M | 11.7M | 9.02M | 7.97M | 6.73M | 6.38M | 5.78M | 5.32M | 6.25M | 6.31M | 6.95M | 6.27M | 6.47M | 5.06M | 6.54M | 3.89M | 3.99M | 3.77M |
| Selling, General, and Administrative Revenue Growth | +4.26% | +8.66% | +7.51% | +7.99% | -0.46% | +4.15% | +2.11% | +4.54% | +7.08% | -11.90% | +32.94% | -5.29% | +13.02% | +0.93% | +32.84% | -9.88% | +11.19% | +26.61% | +21.55% | +49.78% | +51.39% | -2.63% | +31.93% | +29.81% | +13.11% | +18.48% | +5.45% | +10.32% | +8.78% | -14.98% | -0.89% | -9.22% | +10.86% | -3.11% | +27.79% | -22.54% | +68.00% | -2.36% | +5.68% | n/a |
| Research and Development Revenue | 70.29M | 66.82M | 56.18M | 42.83M | 50.77M | 41.55M | 49.79M | 38.02M | 33.86M | 33.27M | 38.54M | 29.04M | 29.46M | 27.03M | 17.3M | 15.06M | 14.3M | 10.28M | 25.2M | 16M | 19.07M | 21.34M | 23.73M | 24.99M | 33.61M | 35.42M | 32.44M | 30.7M | 26.93M | 18.47M | 12.48M | 21.54M | 21.18M | 23.92M | 25.3M | 23.43M | 22.87M | 28.46M | 17.76M | 18.63M |
| Research and Development Revenue Growth | +5.19% | +18.93% | +31.17% | -15.64% | +22.20% | -16.56% | +30.95% | +12.29% | +1.77% | -13.65% | +32.69% | -1.41% | +8.98% | +56.29% | +14.86% | +5.31% | +39.15% | -59.23% | +57.50% | -16.06% | -10.66% | -10.07% | -5.05% | -25.63% | -5.12% | +9.19% | +5.66% | +14.01% | +45.78% | +48.03% | -42.06% | +1.70% | -11.45% | -5.46% | +7.97% | +2.48% | -19.65% | +60.21% | -4.67% | n/a |